{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:51:15Z","timestamp":1790754675848,"version":"4.1.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"\n Objective\/background:<\/jats:title>\n \n B-cell neoplasms are clonal tumors of B cells at various stages of maturation, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic lymphoma (CLL), Burkitt lymphoma (BL), lymphoplasmacytic lymphoma (LPL)\/Waldenstr\u00f6m\u2019s macroglob- ulinemia (WM), splenic marginal zone lymphoma (SMZL), nodal marginal zone lymphoma (NMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and hairy cell leukemia (HCL). In this study, we analyzed the frequency of\n MYD88<\/jats:italic>\n L265P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasms.\n <\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n A total of 110 consecutive cases of B-cell neoplasms showing peripheral blood and\/or bone marrow infiltration were included.\n MYD88<\/jats:italic>\n L265P mutation was detected by polymerase chain reaction amplification of exon 5 of\n MYD88<\/jats:italic>\n gene, followed by restriction fragment length polymorphism analysis.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Among the 110 cases, the major group was of CLL (54.5%,\n n<\/jats:italic>\n = 60), followed by HCL. Other cases included MCL, LPL, DLBCL, SMZL, NMZL, FL, and BL.\n MYD88<\/jats:italic>\n L265P mutation was seen in 21 (19.1%) cases of B-cell neoplasm, whereas 89 (80.9%) cases were negative for\n MYD88<\/jats:italic>\n L265P mutation. It was most commonly seen in LPL\/WM cases followed by HCL, SMZL, CLL, and MCL cases. No case of DLBCL, FL, and BL showed\n MYD88<\/jats:italic>\n L265P mutation. Statistically significant difference was seen for hemoglobin level in CLL cases, with\n MYD88<\/jats:italic>\n L265P mutated cases showing higher mean hemoglobin levels than\n MYD88<\/jats:italic>\n wild-type cases (\n p<\/jats:italic>\n = .001). For other parameters, no statistically significant difference was noted between mutated and unmutated cases.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n MYD88<\/jats:italic>\n L265P mutation is seen in various B-cell neoplasms; it is most commonly seen in LPL\/WM cases but not specific for it.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.10.003","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T01:30:09Z","timestamp":1605231009000},"page":"231-239","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm"],"prefix":"10.4103","volume":"14","author":[{"given":"Raja","family":"Shekhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shano","family":"Naseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jogeshwar","family":"Binota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20241211","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R3-8-20241211","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"key":"R4-8-20241211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/modpathol.3800500","article-title":"Lymphoid neoplasms associated with concurrent t(14;18) and 8q24\/c-MYC translocation generally have a poor prognosis","volume":"19","author":"Kanungo","year":"2006","journal-title":"Mod Pathol"},{"key":"R5-8-20241211","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/blood.V74.5.1796.1796","article-title":"Four new recurring translocations in non-Hodgkin lymphoma","volume":"74","author":"Levine","year":"1989","journal-title":"Blood"},{"key":"R6-8-20241211","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-8-20241211","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"R8-8-20241211","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1309\/AJCP10ZCLFZGYZIP","article-title":"MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lympho-proliferative disorders","volume":"140","author":"Ondrejka","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"R9-8-20241211","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3109\/10428194.2014.924123","article-title":"MYD88 mutant lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart","volume":"56","author":"Patkar","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R10-8-20241211","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"R11-8-20241211","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 mutations and response to ibrutinib in Waldenstrom\u2019s macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-8-20241211","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lympho-plasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"R21-8-20241211","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/leu.2013.294","article-title":"Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders","volume":"28","author":"Argentou","year":"2014","journal-title":"Leukemia"},{"key":"R22-8-20241211","first-page":"564","article-title":"MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma","volume":"28","author":"Hamadeh","year":"2015","journal-title":"Mod Pathol Off JUS Can Acad Pathol Inc"},{"key":"R23-8-20241211","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to","volume":"27","author":"Jim\u00e9nez","year":"2013","journal-title":"Waldenstr\u00f6m\u2019s Macroglobulinemia Leukemia"},{"key":"R24-8-20241211","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstroom macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Gachard","year":"2013","journal-title":"Leukemia"},{"key":"R25-8-20241211","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2013-07-513366","article-title":"MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance","volume":"122","author":"Varettoni","year":"2013","journal-title":"Blood"},{"key":"R26-8-20241211","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstr\u00f6m\u2019s macroglob-ulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.10.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:07Z","timestamp":1787838607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.10.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.10.003","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}